S. 3478
Referred to CommitteeGAIN TOOLS Act of 2022
Latest Action
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
1/11/2022 • Senate
Summary
Generating Antibiotic Incentives Now Through Opening Opportunities to Leverage Science Act of 2022 or the GAIN TOOLS Act of 2022
This bill expands the definition of a qualified infectious disease product (QIDP) to include eligible biological products. Under current law, the first application (or supplement) for a specific product and indication to be designated a QIDP shall receive priority review for market approval by the Food and Drug Administration.
Generally, a biological product designated as a QIDP is one that acts on bacteria or fungi and is intended to treat a serious or life-threatening infection.
However, a biological product with a QIDP designation shall not receive the market exclusivity extension currently available to drugs that receive the designation.
Introduced in Senate • 1/11/2022
Topics & Subjects
Congressional Votes (0)
No recorded votes yet
Roll call votes will appear here as the bill moves through Congress
Related Federal Spending
Sponsor & Cosponsors (3)
Party Breakdown
Sponsor
Cosponsors (2)
Bill Journey
Originated in the Senate
Introduced
January 11, 2022
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Committee Review
Floor Debate
Passed Chamber
Other Chamber
President
Enacted into Law